A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse Xenografts
Open Access
- 27 June 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (6) , e100993
Abstract
The homologous recombination pathway is responsible for the repair of DNA double strand breaks. RAD51, a key homologous recombination protein, promotes the search for homology and DNA strand exchange between homologous DNA molecules. RAD51 is overexpressed in a variety of cancer cells. Downregulation of RAD51 by siRNA increases radio- or chemo-sensitivity of cancer cells. We recently developed a specific RAD51 small molecule inhibitor, B02, which inhibits DNA strand exchange activity of RAD51 in vitro. In this study, we used human breast cancer cells MDA-MB-231 to investigate the ability of B02 to inhibit RAD51 and to potentiate an anti-cancer effect of chemotherapeutic agents including doxorubicin, etoposide, topotecan, and cisplatin. We found that the combination of B02 with cisplatin has the strongest killing effect on the cancer cells. We then tested the effect of B02 and cisplatin on the MDA-MB-231 cell proliferation in mouse xenografts. Our results showed that B02 significantly enhances the therapeutic effect of cisplatin on tumor cells in vivo. Our current data demonstrate that use of RAD51-specific small molecule inhibitor represents a feasible strategy of a combination anti-cancer therapy.Keywords
This publication has 46 references indexed in Scilit:
- ATM is required for the repair of Topotecan-induced replication-associated double-strand breaksRadiotherapy and Oncology, 2013
- Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivityMolecular Cancer Therapeutics, 2009
- Mechanism of Eukaryotic Homologous RecombinationAnnual Review of Biochemistry, 2008
- The consequences of Rad51 overexpression for normal and tumor cellsDNA Repair, 2008
- Cytochrome P450 and Chemical ToxicologyChemical Research in Toxicology, 2007
- The third dimension bridges the gap between cell culture and live tissueNature Reviews Molecular Cell Biology, 2007
- Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulationMolecular Cancer Therapeutics, 2007
- Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicinAnti-Cancer Drugs, 2007
- Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced ApoptosisThe Journal of Pharmacology and Experimental Therapeutics, 2005
- The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent CisplatinJournal of Biological Chemistry, 2000